Submitted by Anonymous (not verified) on 29 July 2024 - 11:08
Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 23, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 23, Status: Authorised